Coronavirus
WHO says it awaits full clinical data from Merck on antiviral pill molnupiravir
The World Health Organization is awaiting full clinical data on the antiviral pill made by Merck & Co Inc to treat mild-to-moderate COVID-19 patients, a WHO spokesperson said on Tuesday, a day after the company said it had applied for US emergency use authorization.
WHO spokesperson Christian Lindmeier, asked at a UN briefing in Geneva about the drug, said: “Indeed, this is an interesting development. We would have to see the full data about it. If it holds true, then it is another weapon in the fight against the COVID-19 pandemic.”
Read the latest updates in our dedicated coronavirus section.
The treatment, molnupiravir, cut the rate of hospitalization and death by 50 percent in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released this month.
For the latest headlines, follow our Google News channel online or via the app.
Read more:
Experts predict ‘severe’ flu season once COVID-19 restrictions relaxed
WHO advises additional COVID-19 shot for immunocompromised people
AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19
Also Read
-
Experts predict ‘severe’ flu season once COVID-19 restrictions relaxed
While the world may be anxious to get back to pre-pandemic living, a new study warns that as soon as COVID-19 precautions end, the flu will make a big ... Coronavirus -
UK waited too long for COVID-19 lockdown: Report
The British government waited too long to impose a lockdown in the early days of the COVID-19 pandemic, missing a chance to contain the disease and ... Coronavirus -
WHO advises additional COVID-19 shot for immunocompromised people
The World Health Organization on Monday recommended that immunocompromised people be given an additional dose of COVID-19 vaccine, due to their higher ... Coronavirus -
Merck applies for US emergency authorization of COVID-19 pill
Merck & Co Inc said on Monday it has applied for emergency use authorization in the US for its oral drug to treat mild-to-moderate patients of ... Coronavirus -
AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19
AstraZeneca’s experimental COVID-19 antibody drug cocktail succeeded in reducing severe disease or death in non-hospitalized patients in a late-stage ... Coronavirus -
More COVID-19 patients developing diabetes as pancreas cells being harmed: Experts
Some COVID-19 patients are developing diabetes symptoms after infection, causing scientists to ask if the virus could trigger the chronic ... Coronavirus
